Alto Neuroscience, Inc. (ANRO)
Automate Your Wheel Strategy on ANRO
With Tiblio's Option Bot, you can configure your own wheel strategy including ANRO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ANRO
- Rev/Share 0.0
- Book/Share 5.1424
- PB 0.6184
- Debt/Equity 0.1901
- CurrentRatio 22.5331
- ROIC -0.4223
- MktCap 86089367.0
- FreeCF/Share -2.0286
- PFCF -1.5689
- PE -1.3614
- Debt/Assets 0.1538
- DivYield 0
- ROE -0.3978
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ANRO | Rodman & Renshaw | Buy | Neutral | -- | -- | Oct. 23, 2024 |
| Downgrade | ANRO | Wedbush | Outperform | Neutral | $29 | $4 | Oct. 23, 2024 |
| Initiation | ANRO | Wedbush | -- | Outperform | -- | $29 | Sept. 3, 2024 |
News
Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc.and Certain Officers – ANRO
Published: August 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-06105, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 2, …
Read More
Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. ("Alto" or the "Company") (NYSE: ANRO) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-06105, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 2, …
Read More
Contact The Gross Law Firm by September 19, 2025 Deadline to Join Class Action Against Alto Neuroscience, Inc.(ANRO)
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE: ANRO). Shareholders who purchased shares of ANRO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Alto Neuroscience, Inc. (NYSE: ANRO)
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Alto Neuroscience, Inc. (NYSE: ANRO)
Read More
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Aug. 11, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE: ANRO) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering ("IPO") conducted on or about February 2, 2024 and/or between February 2, 2024 and October 22, 2024, both dates inclusive (the "Class Period"), are encouraged to contact the firm before September 19, 2025.
Read More
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ANRO
Published: August 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto's initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”), of the important September 19, 2025 lead plaintiff deadline.
Read More
September 19, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ANRO
Published: August 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit.
Read More
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
Published: August 08, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Alto To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Alto (a) Alto common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 2, 2024 (the "IPO" or "Offering"); and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson …
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Alto To Contact Him Directly To Discuss Their Options
Read More
Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc.and Certain Officers – ANRO
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-06105, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 2, …
Read More
ROSEN, LEADING INVESTOR COUNSEL, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ANRO
Published: August 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto's initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”), of the important September 19, 2025 lead plaintiff deadline.
Read More
Alto Neuroscience, Inc. Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – ANRO
Published: August 04, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)---- $ANRO--Alto Neuroscience, Inc. Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – ANRO.
Read More
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
Published: August 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Alto To Contact Him Directly To Discuss Their Options
Read More
Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. ("Alto" or the "Company") (NYSE: ANRO) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-06105, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 2, …
Read More
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit
Published: July 29, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 29, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto's initial public offering conducted on or about February 2, 2024 (the "IPO"); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than September 19, 2025.
Read More
Investors who lost money on Alto Neuroscience, Inc.(ANRO) should contact Levi & Korsinsky about pending Class Action - ANRO
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit.
Read More
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: July 28, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 28, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE: ANRO) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering ("IPO") conducted on or about February 2, 2024 and/or between February 2, 2024 and October 22, 2024, both dates inclusive (the "Class Period"), are encouraged to contact the firm before September 19, 2025.
Read More
Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc.and Certain Officers – ANRO
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-06105, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 2, …
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
Published: July 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Alto To Contact Him Directly To Discuss Their Options
Read More
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: July 25, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 25, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE: ANRO) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering ("IPO") conducted on or about February 2, 2024 and/or between February 2, 2024 and October 22, 2024, both dates inclusive (the "Class Period"), are encouraged to contact the firm before September 19, 2025.
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
Published: July 23, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Alto To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Alto (a) Alto common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 2, 2024 (the "IPO" or "Offering"); and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner …
Read More
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit
Published: July 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 22, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto's initial public offering conducted on or about February 2, 2024 (the "IPO"); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than September 19, 2025.
Read More
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Alto Neuroscience, Inc. (ANRO) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Published: July 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, July 22, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO). The lawsuit alleges that throughout the Class Period, and in the Company's Offering Documents, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information concerning Alto's business, operations, and prospects, including allegations that: (i) ALTO-100 was less effective in treating MDD than Defendants had led investors to believe; (ii) accordingly, ALTO-100's clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Alto's business and/or financial prospects were overstated.
Read More
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Alto Neuroscience, Inc. (ANRO)
Published: July 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Alto Neuroscience, Inc. (“Alto Neuroscience” or the “Company”) (NYSE: ANRO) (i) between February 2, 2024 and October 22, 2024, inclusive (the “Class Period”); and/or (ii) pursuant and/or traceable to Alto Neuroscience's registration statement issued in connection with Alto Neuroscience's February 2, 2024 initial public offering (“IPO”).
Read More
Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
Published: July 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. ("Alto" or the "Company") (NYSE: ANRO) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-06105, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 2, …
Read More
Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway
Published: June 03, 2025 by: Business Wire
Sentiment: Neutral
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that it entered into an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of potentially best-in-class dopamine agonist drug combinations, including ALTO-207, formerly known as CTC-501, for treatment resistant depression (TRD), generally.
Read More
The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
An Investigation Has Been Launched Into Alto Neuroscience, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
About Alto Neuroscience, Inc. (ANRO)
- IPO Date 2024-02-02
- Website https://www.altoneuroscience.com
- Industry Biotechnology
- CEO Amit Etkin
- Employees 76